Industrial automation

Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

AstraZeneca referred to industrial automation the most between October 2020 and September 2021.

Powered by 

Mentions of industrial automation within the filings of companies in the pharmaceutical industry rose 23% between the second and third quarters of 2021.

In total, the frequency of sentences related to industrial automation between October 2020 and September 2021 was 28% lower than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Industrial automation is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether industrial automation is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned industrial automation at least once in filings during the past twelve months - this was 58% compared to 48% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to industrial automation.

Of the 10 biggest employers in the pharmaceutical industry, AstraZeneca Plc was the company which referred to industrial automation the most between October 2020 and September 2021. GlobalData identified 30 industrial automation-related sentences in the United Kingdom-based company's filings - 0.3% of all sentences. Novartis AG mentioned industrial automation the second most - the issue was referred to in 0.18% of sentences in the company's filings.

Across all pharmaceutical companies the filing published in the third quarter of 2021 which exhibited the greatest focus on industrial automation came from Cipla Ltd. Of the document's 4,813 sentences, 19 (0.4%) referred to industrial automation.

This analysis provides an approximate indication of which companies are focusing on industrial automation and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning industrial automation more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into industrial automation have been successes or failures.

In the last quarter, pharmaceutical companies based in Western Europe were most likely to mention industrial automation with 0.11% of sentences in company filings referring to the issue. In contrast, companies with their headquarters in Canada mentioned industrial automation in just 0.01% of sentences.

Go to article: Home | Two years of Covid-19Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: Contract Pharmaceuticals Limited CanadaGo to article: CommentGo to article: Ukraine: Russian invasion could cause spike in Covid-19 cases Go to article: First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvalsGo to article: International Women’s Day spotlight: endometriosisGo to article: Remote audits – stopgap measure or the new normal?Go to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: BaxterGo to article: In DepthGo to article: Two years of Covid-19: lessons the pandemic taught about delivering essential vaccinesGo to article: A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-Go to article: Russia sanctions: what next for Sputnik Covid-19 vaccine production around the wGo to article: Profit for patients: can NFTs allow people to monetise their health data?Go to article: Navigating distribution challenges for rare disease drugsGo to article: NiproGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: North America is seeing a hiring boom in pharma digital media rolesGo to article: Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021Go to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue